Intradetrusor Injections of Botulinum Toxin Type A in Children With Spina Bifida: A Multicenter Study

Archive ouverte

Hascoet, Juliette | Peyronnet, Benoit | Forin, Veronique | Baron, Maximilien | Capon, Grégoire | Prudhomme, Thomas | Allenet, Clément | Tournier, Simon | Maurin, Charlotte | Cornu, Jean-Nicolas | Bouali, Ourdia | Peycelon, Matthieu | Arnaud, Alexis | Renaux-Petel, Mariette | Liard, Agnès | Karsenty, Gilles | Manunta, Andrea | Gamé, Xavier

Edité par CCSD ; Elsevier -

International audience. OBJECTIVE:To assess the effectiveness of intradetrusor injections of botulinum toxin type A (IDBTX-A) in children with spina bifida.METHODS:All patients aged less than 16 years old who underwent IDBTX-A between 2002 and 2016 at 6 institutions were included in a retrospective study. Our primary endpoint was the success rate of IDBTX-A defined as both clinical improvement (no incontinence episodes between clean intermittent catheterizations [CICs], absence of urgency, and less than 8 CICs per day) and urodynamic improvement (resolution of detrusor overactivity and normal bladder compliance for age) lasting ≥12 weeks. Predictive factors of success were assessed through univariate analysis.RESULTS:Fifty-three patients with a mean age of 8.5 years were included. All patients were under CIC and 88.7% had received anticholinergics with either poor efficacy or bothersome adverse events. The global success rate of the first injection (clinical and urodynamic) was 30%. Patients with closed spinal dysraphism had a significantly better success rate than patients with myelomeningocele (P = .002). The clinical success rate was 66% and was significantly associated with maximum urethral closure pressure (34 cm H2O vs 54.4 cm H2O, P = .02). The urodynamic success rate was 34%. Maximum cystometric capacity (P <.0001) and compliance (P = .01) significantly improved after the first IDBTX-A and maximum detrusor pressure tended to decrease (P = .09) except in the subgroup of patients with poor compliance. After a mean follow-up of 3.7 years, 23 patients (43.4%) required augmentation cystoplasty. Excluding 6 patients who were lost to follow-up, 38.3% of patients were still undergoing botulinum toxin injections at last follow-up.CONCLUSION:In this series, despite the fact that IDBTX-A enabled clinical improvement in 66% patients, urodynamic outcomes were poor resulting in a low global success rate (30%).

Consulter en ligne

Suggestions

Du même auteur

Intradetrusor Injections of Botulinum Toxin A in Adults with Spinal Dysraphism

Archive ouverte | Peyronnet, Benoit | CCSD

International audience. Purpose:The aim of the current study was to determine the outcomes of botulinum toxin A intradetrusor injections in adult patients with spina bifida.Materials and methods:All patients with sp...

Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation—A study from the neuro-urology committee of the French Association of Urology

Archive ouverte | Delaval, Stéphanie | CCSD

International audience. Background: While intravesical injections of botulinum neurotoxin A (BoNT-A) are currently recommended for patients experiencing refractory neurogenic overactive bladder and/or detrusor overa...

Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study

Archive ouverte | Baron, Maximilien | CCSD

International audience

Chargement des enrichissements...